Analyzing the slowdown in pharma's digital ad-spend growth
‘Reprioritization’ seen in the marketing mix as the industry finds a new post-COVID equilibrium.
Kimberly Coleman Clotman Amarin Pharma Steve Andrzejewski Coleman Clotman Insider Intelligence Nabriva Therapeutics
Source: mmm-online.com